|1.||van den Wijngaard, R M: 3 articles (12/2013 - 10/2009)|
|2.||Stanisor, O I: 3 articles (12/2013 - 10/2009)|
|3.||Welting, O: 3 articles (12/2013 - 10/2009)|
|4.||Wouters, M M: 3 articles (12/2013 - 10/2009)|
|5.||Boeckxstaens, G E: 3 articles (12/2013 - 10/2009)|
|6.||de Jonge, W J: 3 articles (12/2013 - 10/2009)|
|7.||Bueno, Lionel: 3 articles (08/2010 - 08/2004)|
|8.||Fioramonti, Jean: 3 articles (08/2007 - 08/2003)|
|9.||van Diest, S A: 2 articles (12/2013 - 03/2012)|
|10.||de Jonge, Wouter J: 2 articles (11/2013 - 08/2004)|
|1.||Exercise-Induced Asthma (Asthma, Exercise Induced)
01/03/1977 - "In a double-blind cross-over trial in 13 patients with exercise-induced asthma, doxantrazole 200 mg taken orally 1 hour before a standardized exercise test involving stair climbing failed to block post-exercise bronchoconstriction. "
01/03/1977 - "Exercise-induced asthma and doxantrazole."
12/01/2013 - "In NH-F2 rats, post-WA hypersensitivity was reversed by mast cell stabilizer doxantrazole. "
03/01/2012 - "In contrast, however, the mast cell stabilizer doxantrazole reversed visceral hypersensitivity. "
12/01/2007 - "Furthermore, TNBS-induced visceral hypersensitivity was significantly suppressed by subcutaneous pretreatment with a mast cell stabilizer doxantrazole in a dose-dependent manner. "
12/01/2004 - "Pretreatment of a mast cell stabilizer, doxantrazole (5 mg/kg, i.p.), reduced the degranulation rate of MMC and significantly attenuated visceral hypersensitivity to rectal distension in IBS rat, whereas it had no effect on the visceral sensory responses in normal rat. "
05/01/2001 - "Doxantrazole did not modify the hypersensitivity to GD but prevented mast cell degranulation. "
11/01/2013 - "Doxantrazole and GSK143 significantly increased gastrointestinal transit (GC doxantrazole (10 mg/kg): 7.2 ± 0.7; GSK143 (1 mg/kg): 7.6 ± 0.6), reduced inflammation and prevented recruitment of immune cells in the intestinal muscularis. "
08/01/2004 - "Pretreatment with mast cell stabilizers ketotifen (1 mg/kg, p.o.) or doxantrazole (5 mg/kg, i.p.) prevented both manipulation-induced inflammation and gastroparesis. "
09/01/1995 - "These changes, associated with severe inflammation as assessed histologically and by myeloperoxidase assay, were prevented by doxantrazole or L-NAME, and only partly by MK-886. "
08/01/2007 - "The effect of mast cell stabiliser (doxantrazole, 1 mg/kg intraperitoneally, 2 h before and 6 h after intracolonic infusion of SLIGRL) on SLIGRL-induced visceral hyperalgesia was also assessed. "
08/01/2007 - "4 days of dexamethasone as well as doxantrazole diminished the SLIGRL-induced hyperalgesia for all volumes of distension. "
08/01/2004 - "To determine the involvement of colonic NGF overexpression and mast cell hyperplasia in visceral hyperalgesia induced by MD, neonatally deprived adult rats received anti-NGF antibodies or doxantrazole. "
08/01/2010 - "The effects of minocycline (a microglia inhibitor), nor-binaltorphimine (a kappa-opioid antagonist), and doxantrazole (a mast-cell inhibitor) were observed on morphine-induced visceral hyperalgesia. "
08/01/2010 - "Minocycline reduced the incipient morphine-induced hypersensitivity response to CRD whereas nor-binaltorphimine and doxantrazole antagonized the delayed hyperalgesia. "
|1.||Cromolyn Sodium (Cromoglicic Acid)
|2.||Nerve Growth Factor (NGF)
|4.||NG-Nitroarginine Methyl Ester (L-NAME)
|10.||Morphine (MS Contin)